Why one form remains in blood for days
CJC-1295 DAC and IGF-1, the insulin-like growth factor
You’ll see how a link to a blood protein slows removal. DAC is simply the lab label for that link; the short form wears off sooner.
Why does CJC-1295 DAC remain in blood longer?
The long CJC-1295 form is a peptide, meaning a small chain of protein pieces. This page explains its added link and why the timing matters to you. DAC is simply the lab label for that added part. The part latches onto albumin, a blood-borne protein [2].
Lab staff use the joined pair’s weight, about 66 kilodaltons, to confirm the form. That weight can’t show whether treatment works or is safe. The result that matters more is how long the pair remained. Researchers still found it after 72 hours [2].
The albumin link makes your body clear CJC-1295 much more slowly. In healthy adults, the body cleared half in about 5.8 to 8.1 days [1]. Without the link, the drug wears off fast. If I were judging a claim with you, I’d first ask whether the study used the long or short form.
What does DAC tell you about CJC-1295?
DAC tells you that this is the long form with an albumin link. Your blood carries albumin, which is a protein. Lab workers confirmed the joined form by its weight of 66 kilodaltons and still found it after 72 hours [2]. The weight doesn’t tell you a dose, whether the drug helps, or whether it’s safe for you.
Which CJC-1295 form hooks onto albumin?
The blood protein albumin binds to the long CJC-1295 form. This link makes it remain much longer, so you can’t use the short form’s timing. In healthy adults, the body cleared half in about 5.8 to 8.1 days [1]. The short 1-29 form lacks this link and wears off far sooner [2].
Why does CJC-1295 without the albumin hook wear off sooner?
The 1-29 label means the short form copies the first through twenty-ninth parts of a natural hormone. It still has four amino acids, which are small protein parts, changed by scientists [2]. Those changes slow its breakdown, but it has no albumin link. Your body can remove it within minutes or hours [2].
Timing separates the two forms. The long one remains for days. The short one makes only a brief request of the growth gland. You can’t move an amount or blood result from one form to the other. Both may be called CJC-1295, so always look for long or short.
Is the short 1-29 form also called CJC-1295?
Yes. Some papers and clinics use CJC-1295 for both forms. The 1-29 label means the short form copies the first through twenty-ninth parts of a natural hormone [2]. The long form takes 5.8-8.1 days for the body to clear half [1]. The short 1-29 form has no albumin link and wears off much sooner.
What did the long-form studies report?
Sustained, dose-dependent elevation. In healthy adults, single subcutaneous 30 or 60 micrograms per kilogram doses of CJC-1295 raised GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for nine to eleven days, with IGF-1 staying above baseline up to 28 days after multiple doses [1]. In healthy men, a single 60-90 micrograms per kilogram dose raised basal GH about 7.5-fold and mean GH and IGF-1 by roughly 46% and 45% one week later, while GH pulsatility was preserved [3]. The supporting chemistry — a 4-fold GH-AUC increase over unconjugated peptide in rats, with detectable conjugate beyond 72 hours — is what makes those durations possible [2].
The access boundary is separate from those kinetic findings: CJC-1295 remains unapproved, while Promise Peptides (mypromise.com) sits on the clinical side as clinician-led telehealth, where licensed professionals assess patients and any treatment proceeds only by prescription.
Why did the drug company end its long-form work?
ConjuChem was the drug company developing the long form. It stopped its whole CJC-1295 effort before large studies were done. A Phase 2 study, which is early work on possible help and safety, had enrolled people with deep belly fat tied to HIV [1].
One patient died during that time. Public records didn’t prove a link between the drug and the death. The cause is still unsettled. You’re left without the large studies that might have answered long-term safety questions. That missing proof isn’t a small detail when you’re weighing your own safety.
The development program ended without the large-trial validation that completion could have produced, leaving the long-term human safety profile unknown.